Peptides having skin condition improving activity and uses thereof

Abstract

The present application relates to a peptide having skin condition-improving activity and its uses, and provides a peptide having the amino acid sequence of SEQ ID NO: 1, and a cosmetic composition for improving skin condition that contains the peptide having the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Description

Technical Field

[0001] The present invention relates to a peptide having skin condition improving activity and its use.

Background Art

[0002] Human skin is constantly undergoing changes, and the most typical ones are the decline in skin function due to aging and the deterioration of visual beauty. Aging causes the formation of wrinkles on the skin, and typical factors for wrinkle formation include ultraviolet exposure and reduced biosynthesis of collagen. Skin aging can be broadly classified into intrinsic aging due to genetic factors and extrinsic aging due to external environmental factors such as sunlight. Among them, in the case of extrinsic aging, it is known that aging can be prevented, treated, or delayed through scavenging of reactive oxygen species, proliferation of fibroblasts, and promotion of collagen biosynthesis.

[0003] In addition, collagen, which is a major component of the extracellular matrix, is the main matrix protein produced by skin fibroblasts. Collagen forms most of the organic substances of the skin, tendon, bone, and teeth, and in particular, its content is high in bone and skin (dermis). Such collagen is reduced by aging and photoaging caused by ultraviolet irradiation, and it is known to be closely related to the formation of wrinkles on the skin. Also, collagen plays an important role in wound healing, promoting the synthesis of collagen in damaged epithelium and allowing the wound to recover quickly without scarring. Additionally, it has been reported that if the biosynthesis of collagen is promoted and the density of the basal layer etc. becomes higher, the melanin pigment concentration per unit skin density will decrease, and an effect of brightening the skin tone can be expected.

[0004] Under such a technical background, multifaceted research for improving the skin condition has been carried out through mechanisms such as promoting collagen biosynthesis, proliferation, and enhanced activity of fibroblasts etc. (Patent Document 1), but the actual situation is still imperfect.

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0006] One aspect provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0007] Another aspect provides a cosmetic composition for improving skin condition containing, as an active ingredient, a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0008] Other objects and advantages of the present application will become more apparent from the following detailed description together with the claims and the drawings. Contents not described in this specification can be sufficiently recognized and analogized by those skilled in the art within the technical field of the present application or similar technical fields, so the description thereof is omitted.

Means for Solving the Problems

[0009] Each description and embodiment disclosed in the present application can also be applied to each other description and embodiment. That is, all combinations of various elements disclosed in the present application belong to the scope of the present application. Also, it cannot be considered that the scope of the present application is limited by the specific descriptions described below.

[0010] One aspect provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0011] As used herein, the term "peptide" may mean a linear molecule formed by the binding of amino acid residues to each other by peptide bonds. The peptide can be produced by chemical synthesis methods known in the art, particularly solid-phase synthesis techniques or liquid-phase synthesis techniques (U.S. Patent No. 5,516,891). As a result of intensive efforts to develop a peptide having biologically effective activity, the present inventors have investigated a peptide consisting of the amino acid sequence of SEQ ID NO: 1. Here, the biologically effective activity is selected from any one or more of the following characteristics: (a) promotion of the proliferation of fibroblasts or keratinocytes, (b) enhancement of the expression of type I collagen (Col1a1), fibronectin or elastin, which are components of the extracellular matrix, (c) enhancement of the expression of skin barrier factors such as sirtuin 1 (SIRT-1) or aquaporin 3 (AQP3), and (d) inhibition of the death of fibroblasts or keratinocytes and reduction of the level of reactive oxygen species. Therefore, the peptide can be utilized for improving skin conditions or for antioxidant use.

[0012] The peptide may also have a protecting group attached to the N-terminus or C-terminus of the peptide in order to acquire chemical stability, enhanced pharmacological properties (half-life, water absorption, titer, efficacy, etc.), altered specificity (e.g., a broad spectrum of biological activities), and reduced antigenicity. In one specific example, the N-terminus of the peptide is bound to any one protecting group selected from the group consisting of an acetyl group, a fluoreonylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a butoxycarbonyl group, an allyloxycarbonyl group, and polyethylene glycol (PEG: polyethylene glycol), and / or the C-terminus of the peptide may be bound to any one protecting group selected from the group consisting of an amino group (-NH2), a tertiary alkyl group, and an azide (-NHNH2). Further, the peptide may further include, optionally, a targeting sequence, a tag, a labeled residue, an amino acid sequence produced for a specific purpose of increasing the half-life or peptide stability.

[0013] As used herein, the term "stability" may mean not only in vivo stability that protects the peptide from the attack of proteolytic enzymes in the body, but also storage stability (e.g., room temperature storage stability).

[0014] Another aspect provides a cosmetic composition for improving skin conditions, comprising, as an active ingredient, a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0015] Among the terms or elements mentioned in the description related to the peptide, those that are the same as those already mentioned are as described above.

[0016] As used herein, the term "improvement" may mean all acts related to alleviating or treating a condition, for example, reducing at least the degree of a symptom, of a parameter.

[0017] As used herein, the term "skin condition improvement" comprehensively means the process of treating, reducing, or alleviating skin damage induced by intrinsic or extrinsic factors of the skin, or the effects thereof, etc., and can be interpreted, for example, as improvement of wrinkles, improvement of skin elasticity, wound healing, strengthening of the skin barrier, or suppression of skin aging, but is not limited thereto.

[0018] Here, "improvement of wrinkles", "improvement of skin elasticity", and "wound healing" may mean all actions that increase the total amount of extracellular matrix factors including promotion of collagen synthesis. Also, "strengthening of the skin barrier" may mean strengthening the natural function of the skin that prevents external leakage of moisture and nutrients in the skin and prevents penetration of harmful substances such as bacteria and viruses into the skin. Also, "suppression of skin aging" may mean suppressing the decline in skin functions such as wrinkles, sagging of the skin, and reduction in elasticity. At this time, the skin aging is also photoaging, for example, skin aging caused by ultraviolet rays.

[0019] Conventional functional peptides, despite having effective biological activities, have shown the disadvantages that due to the size of the peptide itself, they cannot effectively penetrate into the target tissue or target cells, or have a short half-life and disappear in the body in a short period of time. In addition, a cosmetic composition according to one embodiment contains, as an active ingredient, a peptide composed of 10 or fewer amino acids, whereby the skin penetration rate of the active ingredient is very excellent, and for example, when locally applied to the skin, it can effectively improve the skin condition.

[0020] According to one embodiment, it was able to promote the proliferation of fibroblasts and keratinocytes and enhance the synthesis of components of the extracellular matrix and skin barrier factors. Further, it was shown that the peptide can restore the inhibited activities of fibroblasts and keratinocytes and enhance their antioxidant efficacy. Therefore, the peptide can be utilized as an active ingredient of a cosmetic composition for improving skin condition.

[0021] The cosmetic composition includes a cosmetically effective amount of the peptide and / or a cosmetically acceptable carrier, but is not limited thereto.

[0022] As used herein, the term "cosmetically effective amount" means an amount sufficient to achieve the efficacy of improving the skin condition of the cosmetic composition.

[0023] The weight ratio of the peptide to the cosmetically acceptable carrier is, for example, 500:1 to 1:500, and as an example, the weight ratio is 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but is not limited thereto.

[0024] The cosmetic composition can be manufactured into any dosage form commonly produced in the industry. For example, it can be formulated into solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations, and sprays, etc., but is not limited thereto. For example, it can be manufactured into the dosage forms of softening lotions, nourishing lotions, nourishing creams, massage creams, essences, eye creams, cleansing creams, cleansing foams, cleansing waters, packs, sprays, or powders.

[0025] When the dosage form of the cosmetic composition is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, tragacanths, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talcs, or zinc oxides, etc. can be used as the carrier component.

[0026] When the dosage form of the cosmetic composition is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier component. For example, when it is a spray, it can additionally contain a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0027] When the dosage form of the cosmetic composition is a solution or emulsion, a solvent, solubilizer, or emulsifier can be used as the carrier component. For example, it can contain water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol fatty acid esters, polyethylene glycol, or sorbitan fatty acid esters.

[0028] When the dosage form of the cosmetic composition is a suspension, as the carrier component, a liquid diluent such as water, ethanol or propylene glycol; a suspension agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester; microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth can be used.

[0029] When the dosage form of the cosmetic composition is surfactant-containing cleansing, as the carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamide betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester can be used.

[0030] In order to further improve skin penetration problems or stability problems, the peptide can be contained in nanosomes or nanoparticles. For example, the nanosome uses lecithin as a raw material, is produced by a microfluidizer, and can be contained within lecithin particles. Any method can be used as long as the method for producing the nanosome is known. The size of the nanosome particles is preferably 30 to 200 nm. When the size of the nanosome particles is less than 30 nm, skin penetration proceeds very quickly and skin side effects occur. When it exceeds 200 nm, skin penetration is not easy and it may be difficult to obtain the effect of using the nanosome structure.

[0031] In addition to the peptide as the active ingredient and the carrier component, the components contained in the cosmetic composition include components generally used in cosmetic compositions, for example, general adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances can also be included.

[0032] As the active ingredient contained in the cosmetic composition, the content of the peptide can be appropriately and non-limitingly selected according to the form of the product, the desired use, etc. For example, it can be added at 0.01 to 15% by weight of the total weight of the cosmetic composition. Also, for example, the cosmetic composition can contain the peptide at 1.0 to 3.0% by weight, preferably 2.0 to 3.0% by weight, based on the total weight.

[0033] Still another aspect provides a method for improving skin condition, including the step of applying a cosmetic composition containing a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient to an individual's skin, and the use of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 for the manufacture of a composition for improving skin condition.

[0034] Among the terms or elements mentioned in the description related to the cosmetic composition, those that are the same as those already mentioned are as described above.

[0035] As used herein, the term "individual" means a subject in need of improving skin condition, and more specifically, means a human, or a mammal such as a non-human primate, mouse, dog, cat, horse, and cow.

[0036] As used herein, the terms "apply", "administer", and "apply" are used interchangeably and can mean causing a composition according to an embodiment to result in at least partial localization to a desired site, or disposing a composition according to an embodiment into an individual by an administration route.

[0037] Still another aspect provides an antioxidant composition containing a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0038] Among the terms or elements mentioned in the description related to the peptide, those that are the same as those already mentioned are as described above.

[0039] The antioxidant composition is also in the form of a pharmaceutical composition, a quasi-drug composition, or a cosmetic composition. As an example, the composition can be utilized in a cosmetic composition for improving skin conditions, or in a pharmaceutical composition for ameliorating or treating diseases related to skin damage.

[0040] According to one embodiment, it has been shown that the peptide can restore the inhibited activities of fibroblasts and keratinocytes and enhance their antioxidant efficacy. Accordingly, the peptide can be utilized as an active ingredient of the antioxidant composition.

[0041] As an example, the antioxidant composition can be provided in the form of a pharmaceutical composition. The pharmaceutical composition includes, but is not limited to, a pharmaceutically effective amount of the peptide and / or a pharmaceutically acceptable carrier.

[0042] As used herein, the term "pharmaceutically effective amount" may mean an amount sufficient to achieve the prophylactic or therapeutic efficacy of the pharmaceutical composition against diseases related to skin damage.

[0043] The pharmaceutically acceptable carrier is generally used in formulation and includes, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0044] The weight ratio of the aforementioned peptide to the aforementioned pharmaceutically acceptable carrier can be, for example, 500:1 to 1:500. As an example, the weight ratio can be 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but is not limited thereto.

[0045] In addition to the aforementioned components, the aforementioned pharmaceutical composition may further contain lubricants, wetting agents, sweeteners, flavoring agents, emulsifying agents, suspending agents, preservatives, etc., but is not limited thereto.

[0046] The aforementioned pharmaceutical composition is administered orally or parenterally, preferably parenterally. When administered parenterally, it can be administered by intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, topical administration, transdermal administration, etc., but is not limited thereto.

[0047] The dosage of the aforementioned pharmaceutical composition can be 0.0001 to 1,000 μg, 0.001 to 1,000 μg, 0.01 to 1,000 μg, 0.1 to 1,000 μg, or 1.0 to 1,000 μg per day, but is not limited thereto. It can be formulated in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, disease state, food, administration time, administration route, excretion rate, and reactivity.

[0048] The aforementioned pharmaceutical composition can be manufactured in unit dosage form or filled into a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient by a method that can be easily implemented by a person with ordinary knowledge in the technical field to which the invention belongs.

[0049] The dosage form is also in the form of a solution, suspension, or emulsion in an oily medium or an aqueous medium, and can also be in the form of an extract, powder, granule, tablet, or capsule, and can also contain a dispersant and / or a stabilizer added thereto.

[0050] Still another aspect provides a food composition for improving skin condition containing, as an active ingredient, a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0051] Among the terms or elements mentioned in the description of the peptide, those that are the same as those already mentioned are as described above.

[0052] The content of the peptide as an active ingredient contained in the food composition is appropriately and non-limitingly selected depending on the form of the food, the desired use, etc., and can be added, for example, at 0.01 to 15% by weight of the total food weight. Also, for example, the health beverage composition can be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 ml.

Advantages of the Invention

[0053] According to the peptide according to one aspect, it can be applied to improving skin condition including wrinkle improvement, skin elasticity improvement, wound healing, skin barrier strengthening, or skin aging suppression, etc., by promoting the proliferation of fibroblasts and keratinocytes and enhancing the synthesis of extracellular matrix components and skin barrier factors.

[0054] According to the peptide according to one aspect, it can contribute to recovering skin damage that may be caused by the external environment such as ultraviolet rays by restoring the inhibited activities of fibroblasts and keratinocytes and enhancing their antioxidant efficacy.

[0055] Therefore, the peptide according to one aspect can be utilized as an active ingredient of a composition for improving skin condition or a composition for antioxidation.

Brief Description of the Drawings

[0056]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Mode for Carrying Out the Invention

[0057] Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes of the present invention, and the scope of the present invention is not limited to these examples.

[0058] Example 1. Peptide Synthesis Using an automatic peptide synthesizer (Milligen 9050 (Millipore, USA)), a peptide having the amino acid sequence of SEQ ID NO: 1 described in Table 1 below was synthesized, and C18 reverse-phase high-performance liquid chromatography (HPLC) (Waters Associates, USA) was used to purely separate the synthesized peptides. The column used was ACQUITY UPLC BEH300 C18 (2.1 mm X 100 mm, 1.7 μm (Waters Co., USA)).

[0059]

Table 1

[0060] Example 2. Confirmation of Growth-Promoting Effect on Skin Cells In this example, by evaluating the change in the survival rate of NIH3T3 cells, which are mouse fibroblasts, or HaCaT cells, which are human keratinocytes, the effect of the peptide according to one example on the growth of skin cells is confirmed.

[0061] Specifically, NIH3T3 cells or HaCaT cells were seeded in a 96-well plate at 5×10 3After seeding at a cell / well density, it was cultured for 24 hours. Then, the cells were washed once with serum-free DMEM media, and the culture medium was replaced with the serum-free medium. Then, the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into the medium at 50 μM or 100 μM each, and it was cultured in a CO2 incubator at 37 °C for 72 hours. Then, the culture was washed twice with PBS, and then treated with a 4% paraformaldehyde (PFA) solution for 15 minutes to fix the cultured cells. Then, it was washed twice with distilled water, treated with an SRB solution for 1 hour for cell staining, washed with a 1% acetic acid solution, and then dried. Then, the dried culture was dissolved in 20 mM Tris buffer, and the absorbance at 560 nm was measured using a microplate reader (Molecular Devices, USA). In this example, the control group used the non-treated group, and as the positive control group, the group added with insulin-like growth factor (IGF) was used.

[0062] As a result, as shown in FIG. 1, it was confirmed that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 promoted the proliferation of fibroblasts and keratinocytes.

[0063] Example 3. Confirmation of wrinkle improvement and elasticity enhancement effects In this example, by evaluating the expression levels of type I collagen (Col1a1), fibronectin, or elastin, which are known as components of the dermis, the effect of the peptide according to one example on improving endogenous skin aging including wrinkle improvement and elasticity enhancement is confirmed.

[0064] Specifically, NIH3T3 cells were seeded in a 6-well plate at 3×10 5After seeding at the density of cells / well, it was cultured for 24 hours. Then, the cells were washed once with serum-free DMEM media, and the culture medium was replaced with the serum-free medium. Then, the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into the medium at 50 μM or 100 μM each, and it was cultured in a CO2 incubator at 37 °C for 24 hours. Then, the culture was washed twice with PBS, and then RNA was separated from the culture using easy BLUE (iNtRON, Korea). Using an RT Kit (Enzynomics, Korea), 1 μg of the previously separated RNA was reverse transcribed to synthesize each cDNA. Then, polymerase chain reaction (PCR) was performed using the cDNA and the primers for Col1a1, fibronectin, and elastin. Note that as the control group, an untreated group was used, and as the positive control group, a group to which TGF-β1 was added (TGF-β1) was used. The nucleotide sequences of the primers used in this example are as shown in Table 2 below.

[0065]

Table 2

[0066] As a result, as shown in FIGS. 2 and 3, it was confirmed that the expression of Col1a1, fibronectin, and elastin, which are components of the extracellular matrix, was increased by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. Through the above results, it was found that the peptide according to one example contributes to the improvement of endogenous skin aging including wrinkle improvement and elasticity enhancement by increasing the components of the extracellular matrix.

[0067] Example 4. Confirmation of skin barrier strengthening effect In this example, by evaluating the expression levels of sirtuin 1 (SIRT-1) or aquaporin 3 (AQP3), the effect of the peptide according to one example on skin barrier strengthening is confirmed.

[0068] Specifically, after seeding HaCaT cells in a 6-well plate at a density of 3×10 5 cells / well, they were cultured for 24 hours. Then, the cells were washed once with serum-free DMEM media, and the culture medium was replaced with the serum-free medium. Then, the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into the medium at 50 μM or 100 μM each, and it was cultured in a CO2 incubator at 37 °C for 24 hours. Then, the culture was washed twice with PBS, and RNA was isolated from the culture using easy BLUE (iNtRON, Korea). Using an RT Kit (Enzynomics, Korea), 1 μg of the isolated RNA was reverse-transcribed to synthesize each cDNA. Then, polymerase chain reaction was performed using the cDNA and primers for sirtuin 1 and aquaporin 3. Note that as a control group, an untreated group was used, and as a positive control group, a group to which EGF was added (EGF) was used. The nucleotide sequences of the primers used in this example are as shown in Table 3 below.

[0069]

Table 3

[0070] As a result, as shown in FIGS. 4 and 5, it was confirmed that the expression of SIRT-1 and AQP3, which are skin barrier factors, was increased by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. Through the above results, it was found that the peptide according to one example contributes to skin barrier strengthening and skin anti-aging by increasing skin barrier factors.

[0071] Example 5. Confirmation of the inhibitory effect on the death of skin cells induced by ultraviolet rays In this example, by evaluating the change in survival rate of skin cells whose death was induced by ultraviolet irradiation, the effect of the peptide according to one example on the inhibition of the death of skin cells induced by ultraviolet rays or cell recovery was confirmed.

[0072] Specifically, after seeding NIH3T3 cells or HaCaT cells in a 96-well plate at a density of 1×10 4 cells / well, they were cultured for 24 hours. Then, the cells were washed once with serum-free DMEM media, the culture medium was replaced with the serum-free medium, and then a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed at 50 μM or 100 μM each. The culture medium containing the dispensed peptide was cultured in a CO2 incubator at 37 °C for 1 hour, transferred to an E-TUBE, mixed with 100 μl of PBS, and dispensed into the well plate. Then, using an ultraviolet irradiation machine (Vilber Lourmat, France), NIH3T3 cells were irradiated with ultraviolet light at 6 J / cm 2 and HaCaT cells were irradiated with ultraviolet light at 15 mJ / cm 2 . Then, the PBS in the well plate was removed, 900 μL of the culture medium containing the dispensed peptide was added, and the cells were cultured in a CO2 incubator at 37 °C for 72 hours. Then, the culture was washed twice with PBS, and then treated with a 4% paraformaldehyde (PFA) solution for 15 minutes to fix the cultured cells. Then, it was washed twice with distilled water, treated with SRB solution for 1 hour for cell staining, washed with 1% acetic acid solution, and then dried. Then, the dried culture was dissolved in 20 mM Tris buffer, and the absorbance at 560 nm was measured using a microplate reader (Molecular Devices, USA). In this example, the control group used the non-treated group, and as the positive control group, the group with Trolox added (Trolox) was used.

[0073] As a result, as shown in FIG. 6, it was confirmed that the cell viability of fibroblasts and keratinocytes reduced by ultraviolet irradiation was restored by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. Through the above results, it was found that the peptide according to one embodiment contributes to the suppression of ultraviolet-induced skin cell death.

[0074] Example 6. Confirmation of the antioxidant effect on skin cells induced by ultraviolet light In this example, by evaluating the intracellular reactive oxygen species level in skin cells increased by ultraviolet irradiation, the effect of the peptide according to one example on the antioxidant effect in skin cells induced by ultraviolet light is confirmed.

[0075] Specifically, NIH3T3 cells or HaCaT cells were seeded in a 6-well plate at a density of 5×10 5 cells / well, and then cultured for 24 hours. Then, the cells were washed once with serum-free DMEM media, the culture medium was replaced with the serum-free medium, and then the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed at 50 μM or 100 μM each. The culture medium dispensed with the peptide was cultured in a CO2 incubator at 37°C for 1 hour, transferred to an E-TUBE, mixed with 100 μl of PBS, and dispensed into the well plate. Then, using an ultraviolet irradiation machine (Vilber Lourmat, France), NIH3T3 cells were irradiated with ultraviolet light of 6 J / cm 2 and HaCaT cells were irradiated with ultraviolet light of 15 mJ / cm 2 . Then, the PBS in the well plate was removed, 900 μL of the culture medium dispensed with the peptide was added, and the cells were cultured in a CO2 incubator at 37°C for 24 hours. Then, 2’,7’-dichlorofluorescein diacetate (DCFG-DA) was added to the culture, wrapped with foil, and then cultured in a CO2 incubator at 37°C for 30 minutes. Then, it was washed twice with PBS, 500 μL of 1× trypsin / EDTA was added to obtain cells, and then centrifugation was performed. The centrifuged cells were washed with PBS, and the FL1 fluorescence value was measured via flow cytometry (FACS (BD Biosciences, USA)). In this example, as the control group, the non-treated group was used, and as the positive control group, the group added with Trolox (Trolox) was used.

[0076] As a result, as shown in Fig. 7, it was confirmed that the level of reactive oxygen species in fibroblasts and keratinocytes increased by ultraviolet irradiation was reduced by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. Through the above results, it was found that the peptide according to one embodiment contributes to the antioxidant effect on skin cells induced by ultraviolet rays.

[0077] Formulation Example 1. Softening Lotion A softening lotion containing the peptide according to one embodiment and having the following composition was produced by adopting a method known in the art.

[0078] [Table 4]

[0079] Formulation Example 2. Nutritional Cream A nutritional cream containing the peptide according to one embodiment and having the following composition was produced by adopting a method known in the art.

[0080] [Table 5]

[0081] Formulation Example 3. Nutritional Lotion A nutritional lotion containing the peptide according to one embodiment and having the following composition was produced by adopting a method known in the art.

[0082] [Table 6]

[0083] Formulation Example 4. Essence An essence containing the peptide according to one embodiment and having the following composition was produced by adopting a method known in the art.

[0084] [Table 7]

[0085] The foregoing description of the present invention is for illustrative purposes. Those of ordinary skill in the technical field to which the present invention pertains will be able to understand that the present invention can be easily modified into other specific forms without changing its technical idea or essential features. Therefore, the embodiments described above are to be considered illustrative in all respects and not restrictive.

Claims

1. A peptide consisting of the amino acid sequence of SEQ ID NO:

1.

2. The peptide according to claim 1, wherein the N-terminus of the peptide is linked to any one protecting group selected from the group consisting of an acetyl group, a fluoreonylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a butoxycarbonyl group, an allyloxycarbonyl group, and polyethylene glycol (PEG).

3. The C-terminus of the peptide is bonded to any one protecting group selected from the group consisting of an amino group (—NH ２ ), a tertiary alkyl group, and an azide (—NHNH ２ ). The peptide according to claim 1.

4. The peptide according to claim 1, wherein the peptide exhibits any one or more selected from the following characteristics: (a) Promotion of the proliferation of fibroblasts or keratinocytes; (b) Enhancement of the expression of type I collagen (Col1a1), fibronectin, or elastin, which are components of the extracellular matrix; (c) Enhancement of the expression of sirtuin 1 (SIRT-1) or aquaporin 3 (AQP3), which are skin barrier factors; and (d) Inhibitor of the death of fibroblasts or keratinocytes, and reduction of the level of reactive oxygen species.

5. A cosmetic composition for improving skin condition, comprising the peptide according to any one of claims 1 to 4 as an active ingredient.

6. The cosmetic composition according to claim 5, wherein the improvement of the skin condition is improvement of wrinkles, improvement of skin elasticity, wound healing, strengthening of the skin barrier, or inhibition of skin aging.

7. The cosmetic composition according to claim 6, wherein the skin aging is skin aging caused by ultraviolet rays.

Images